2001
DOI: 10.1016/s0301-472x(00)00621-4
|View full text |Cite
|
Sign up to set email alerts
|

Bone marrow stem cell protection from chemotherapy by low–molecular-weight compounds

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

3
6
0
3

Year Published

2003
2003
2021
2021

Publication Types

Select...
5
3

Relationship

0
8

Authors

Journals

citations
Cited by 23 publications
(12 citation statements)
references
References 143 publications
3
6
0
3
Order By: Relevance
“…34 On the other hand, other reports have shown that the existence of circulating BM endothelial progenitor cells can restore blood flow to ischemic animals leading to the concept of 'therapeutic adult vasculogenesis' that may explain the recruitment of ECs to various target organs such as BM, where they might contribute to the in situ neo-vascularization. [33][34][35][36][37][38][39][40] This phenomenon may sustain a physiological angiogenesis process, which is probably essential for tissue repair, remodeling, and regeneration and these are in line with our results, since the number of CFU-En from patients in remission phase positively correlated with the frequency of BM CFU-GM colonies, possibly suggesting a parallel process of bone marrow reconstitution. [33][34][35][36][37][38][39][40] In conclusion, Endothelial colonies in non-Hodgkin's lymphomaour in vitro data have shown that NHL patients in remission state have higher numbers of CFU-En than that of newly diagnosed subjects, thus providing a rationale for further investigating the effects of different cytostatic drugs on endothelial cells growth and function.…”
Section: Discussionsupporting
confidence: 86%
See 2 more Smart Citations
“…34 On the other hand, other reports have shown that the existence of circulating BM endothelial progenitor cells can restore blood flow to ischemic animals leading to the concept of 'therapeutic adult vasculogenesis' that may explain the recruitment of ECs to various target organs such as BM, where they might contribute to the in situ neo-vascularization. [33][34][35][36][37][38][39][40] This phenomenon may sustain a physiological angiogenesis process, which is probably essential for tissue repair, remodeling, and regeneration and these are in line with our results, since the number of CFU-En from patients in remission phase positively correlated with the frequency of BM CFU-GM colonies, possibly suggesting a parallel process of bone marrow reconstitution. [33][34][35][36][37][38][39][40] In conclusion, Endothelial colonies in non-Hodgkin's lymphomaour in vitro data have shown that NHL patients in remission state have higher numbers of CFU-En than that of newly diagnosed subjects, thus providing a rationale for further investigating the effects of different cytostatic drugs on endothelial cells growth and function.…”
Section: Discussionsupporting
confidence: 86%
“…[33][34][35][36][37][38][39][40] This phenomenon may sustain a physiological angiogenesis process, which is probably essential for tissue repair, remodeling, and regeneration and these are in line with our results, since the number of CFU-En from patients in remission phase positively correlated with the frequency of BM CFU-GM colonies, possibly suggesting a parallel process of bone marrow reconstitution. [33][34][35][36][37][38][39][40] In conclusion, Endothelial colonies in non-Hodgkin's lymphomaour in vitro data have shown that NHL patients in remission state have higher numbers of CFU-En than that of newly diagnosed subjects, thus providing a rationale for further investigating the effects of different cytostatic drugs on endothelial cells growth and function. However, based on results on BM hematopoietic colony assays and on previously published papers the data here presented seem to suggest that human bone marrow endothelial cells could also be involved in mechanisms, which are different from tumor angiogenesis, such as hematopoietic cell preservation and physiological repair after chemotherapy.…”
Section: Discussionsupporting
confidence: 86%
See 1 more Smart Citation
“…[1][2][3][4][5][6] In this way, they may prevent DNA breakage during the S phase and subsequent apoptosis. One of these negative regulators, the tetrapeptide AcSDKP (acetyl-N-Ser-Asp-Lys-Pro), has been evaluated in preclinical studies.…”
Section: Introductionmentioning
confidence: 99%
“…While , 2005), protection of bone marrow stem cells during chemotherapy (Guest and Uetrecht, 2001) and restoration of dopaminergic neurons in a Parkinson's disease model (Sredni et al, 2007). Despite their interesting physiological and beneficial properties, organochalcogens can be toxic.…”
Section: Introductionmentioning
confidence: 99%